| Active ingredient (INN) | Dalbavancin |
|---|---|
| Brand names | Xydalba |
| ATC level 5 | J01XA04 |
| ATC level 4 |
| J01XA |
| Therapeutic category | Auto-created by Health Canada — Drug Shortages Database scraper |
|---|
| Controlled substance | No |
|---|
| Marketing-authorisation holders | TEVA PHARMACEUTICALS, INC., FRESENIUS KABI USA, LLC, Long Grove Pharmaceuticals, LLC |
|---|
| Registrations on file | 3 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| Dalbavancin | 500mg/25mL | injection | 🇺🇸 US | TEVA PHARMACEUTICALS, INC. | Active |
| Dalbavancin Hydrochloride | 500mg/25mL | injection | 🇺🇸 US | FRESENIUS KABI USA, LLC | Active |
| Dalbavancin | 500mg/1 | injection | 🇺🇸 US | Long Grove Pharmaceuticals, LLC | Active |